Published in Cell Oncol on January 01, 2009
The molecular biology of head and neck cancer. Nat Rev Cancer (2010) 9.84
Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature (2015) 5.50
The molecular pathogenesis of head and neck squamous cell carcinoma. J Clin Invest (2012) 1.86
Two distinct routes to oral cancer differing in genome instability and risk for cervical node metastasis. Clin Cancer Res (2011) 1.06
Advances in the management of squamous cell carcinoma of the head and neck. F1000Prime Rep (2014) 1.00
Basics of tumor development and importance of human papilloma virus (HPV) for head and neck cancer. GMS Curr Top Otorhinolaryngol Head Neck Surg (2012) 0.94
Genomic landscape of metastatic colorectal cancer. Nat Commun (2014) 0.89
Genomic profiling identifies common HPV-associated chromosomal alterations in squamous cell carcinomas of cervix and head and neck. BMC Med Genomics (2009) 0.89
Distinct effects of alcohol consumption and smoking on genetic alterations in head and neck carcinoma. PLoS One (2013) 0.87
Unraveling the molecular genetics of head and neck cancer through genome-wide approaches. Genes Dis (2014) 0.83
Moving towards personalised therapy in head and neck squamous cell carcinoma through analysis of next generation sequencing data. Eur J Cancer (2016) 0.79
Current potential and limitations of molecular diagnostic methods in head and neck cancer. Eur Arch Otorhinolaryngol (2010) 0.77
Phylogenetic analysis of multiple FISH markers in oral tongue squamous cell carcinoma suggests that a diverse distribution of copy number changes is associated with poor prognosis. Int J Cancer (2015) 0.76
Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer. Oncotarget (2016) 0.75
Possibility of the use of public microarray database for identifying significant genes associated with oral squamous cell carcinoma. Genomics Inform (2012) 0.75
Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients. Oncotarget (2016) 0.75
The molecular biology of head and neck cancer. Nat Rev Cancer (2010) 9.84
Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer (2008) 7.99
Dissecting the metastatic cascade. Nat Rev Cancer (2004) 6.32
Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One (2008) 5.86
A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res (2003) 5.04
High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol (2007) 4.70
A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer (2007) 4.29
Recruitment to the nuclear periphery can alter expression of genes in human cells. PLoS Genet (2008) 3.75
Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst (2004) 3.67
Resolving the resolution of array CGH. Genomics (2007) 3.66
Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood (2008) 3.65
Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer (2006) 3.34
BAC to the future! or oligonucleotides: a perspective for micro array comparative genomic hybridization (array CGH). Nucleic Acids Res (2006) 3.32
Breakpoint identification and smoothing of array comparative genomic hybridization data. Bioinformatics (2004) 2.85
CGHcall: calling aberrations for array CGH tumor profiles. Bioinformatics (2007) 2.83
Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS (2003) 2.78
Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res (2006) 2.71
Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol (2007) 2.47
Magnetic resonance imaging pattern recognition in hypomyelinating disorders. Brain (2010) 2.19
Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation: clinical and genetic characterization and target for therapy. Brain (2014) 2.14
Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program. Int J Radiat Oncol Biol Phys (2008) 2.13
Transcription forms and remodels supercoiling domains unfolding large-scale chromatin structures. Nat Struct Mol Biol (2013) 2.09
Human and mouse oligonucleotide-based array CGH. Nucleic Acids Res (2005) 2.03
In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res (2005) 1.76
Oral malignant melanoma: a review of the literature. Oral Oncol (2006) 1.70
Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med (2009) 1.68
Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med (2006) 1.62
Effects of dependence in high-dimensional multiple testing problems. BMC Bioinformatics (2008) 1.59
(89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med (2005) 1.56
Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther (2002) 1.52
Nanocolloidal albumin-IRDye 800CW: a near-infrared fluorescent tracer with optimal retention in the sentinel lymph node. Eur J Nucl Med Mol Imaging (2012) 1.49
TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst (2004) 1.45
Smoothing waves in array CGH tumor profiles. Bioinformatics (2009) 1.45
Selective neck dissection in the management of the neck after (chemo)radiotherapy for advanced head and neck cancer. Proposal for a classification update. Head Neck (2010) 1.42
Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. Gut (2012) 1.42
Oral and oropharyngeal cancer in The Netherlands between 1989 and 2006: Increasing incidence, but not in young adults. Oral Oncol (2009) 1.41
Second primary tumors and field cancerization in oral and oropharyngeal cancer: molecular techniques provide new insights and definitions. Head Neck (2002) 1.41
Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients. J Transl Med (2013) 1.40
Somatic mutations found in the healthy blood compartment of a 115-yr-old woman demonstrate oligoclonal hematopoiesis. Genome Res (2014) 1.40
Primary lung cancer after treatment of head and neck cancer without lymph node metastasis: is there a role for autofluorescence bronchoscopy? Lung Cancer (2008) 1.39
Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer (2005) 1.39
Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities. Eur J Nucl Med Mol Imaging (2002) 1.36
Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging (2008) 1.36
Clinical and molecular characteristics of squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst (2008) 1.36
A genetic progression model of oral cancer: current evidence and clinical implications. J Oral Pathol Med (2004) 1.36
Advances and applications of oral cancer basic research. Oral Oncol (2011) 1.33
Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm. Int J Cancer (2012) 1.31
Predictive modelling for swallowing dysfunction after primary (chemo)radiation: results of a prospective observational study. Radiother Oncol (2011) 1.31
A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res (2006) 1.30
ACE-it: a tool for genome-wide integration of gene dosage and RNA expression data. Bioinformatics (2006) 1.29
A predictive model for swallowing dysfunction after curative radiotherapy in head and neck cancer. Radiother Oncol (2009) 1.28
Nonparametric testing for DNA copy number induced differential mRNA gene expression. Biometrics (2008) 1.27
Integrated genomic and transcriptional profiling identifies chromosomal loci with altered gene expression in cervical cancer. Genes Chromosomes Cancer (2008) 1.26
Elective and therapeutic selective neck dissection. Oral Oncol (2005) 1.26
Across array comparative genomic hybridization: a strategy to reduce reference channel hybridizations. Genes Chromosomes Cancer (2008) 1.25
Quality of life and functional status in patients with cancer of the oral cavity and oropharynx: pretreatment values of a prospective study. Eur Arch Otorhinolaryngol (2007) 1.24
Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol Cancer Ther (2008) 1.24
Management of Frey syndrome. Head Neck (2007) 1.24
Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: a prospective study. Clin Cancer Res (2004) 1.24
CGHMultiArray: exact P-values for multi-array comparative genomic hybridization data. Bioinformatics (2005) 1.23
Exonic deletions in AUTS2 cause a syndromic form of intellectual disability and suggest a critical role for the C terminus. Am J Hum Genet (2013) 1.22
Microarray analysis reveals pivotal divergent mRNA expression profiles early in the development of either compensated ventricular hypertrophy or heart failure. Physiol Genomics (2005) 1.22
Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. Cancer Res (2008) 1.21
Determination of amplicon boundaries at 20q13.2 in tissue samples of human gastric adenocarcinomas by high-resolution microarray comparative genomic hybridization. J Pathol (2003) 1.21
Weighted clustering of called array CGH data. Biostatistics (2007) 1.21
Multiple head and neck tumors frequently originate from a single preneoplastic lesion. Am J Pathol (2002) 1.20
Expanding fields of genetically altered cells in head and neck squamous carcinogenesis. Semin Cancer Biol (2005) 1.20
Relevance of PTEN loss in brain metastasis formation in breast cancer patients. Breast Cancer Res (2012) 1.20
Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion. Clin Cancer Res (2009) 1.19
Genetically altered fields as origin of locally recurrent head and neck cancer: a retrospective study. Clin Cancer Res (2004) 1.18
Screening for distant metastases in head and neck cancer patients by chest CT or whole body FDG-PET: a prospective multicenter trial. Radiother Oncol (2008) 1.17
Identification of key genes for carcinogenic pathways associated with colorectal adenoma-to-carcinoma progression. Tumour Biol (2010) 1.16
Preprocessing and downstream analysis of microarray DNA copy number profiles. Brief Bioinform (2010) 1.16
TPX2 and AURKA promote 20q amplicon-driven colorectal adenoma to carcinoma progression. Gut (2011) 1.15